In Conversation

Fernando Fogarin – Strategic Project Lead Emerging Markets, Organon

Fernando Fogarin – Strategic Project Lead Emerging Markets, Organon

By addressing women's health, we positively impact the entire community. A healthy, empowered woman leads to a resilient family and a stronger society
Yu Wang – Chairman, Chinese Foundation for Hepatitis Prevention & Control

Yu Wang – Chairman, Chinese Foundation for Hepatitis Prevention & Control

The regulatory environment in China, guided by the NMPA, appears to be evolving positively, providing a conducive framework for pharmaceutical innovation and growth
Walid Tohme – Partner, Strategy& Middle East, PwC

Walid Tohme – Partner, Strategy& Middle East, PwC

Aligning multiple stakeholders in Saudi Arabia's healthcare transformation is pivotal yet challenging. With the creation of new entities alongside the transformation of existing ones, establishing cohesive governance and operational models becomes crucial
Diana Liu – General Manager, Roche Hong Kong & Macau

Diana Liu – General Manager, Roche Hong Kong & Macau

These three elements—expertise, quality, and efficiency—make Hong Kong a unique and valuable location for our clinical trials
Sabrina Chan – Senior Executive Director, Hong Kong Association of the Pharmaceutical Industry (HKAPI)

Sabrina Chan – Senior Executive Director, Hong Kong Association of the Pharmaceutical Industry (HKAPI)

What is critical here is to ensure Hong Kong's regulatory framework remains aligned with international standards and being recognized by many markets
Lionel Collet – President, Haute Autorité de Santé (HAS), France

Lionel Collet – President, Haute Autorité de Santé (HAS), France

Maintaining independence is paramount because we must never be beholden, in any way, to either industry interests or governmental influence.
Mohammed Khalil – CEO, SAJA Pharmaceuticals

Mohammed Khalil – CEO, SAJA Pharmaceuticals

Our goal is to ensure that the right medication is available at the right time and at a fair price
Sarah McMullen, Country Director, FDA India Office

Sarah McMullen, Country Director, FDA India Office

As the saying goes – “a rising tide lifts all boats”, and we would expect that universal implementation of GMPs would buoy product quality among those firms in compliance
Monica Bettencourt-Dias – Principal Investigator & Former Director, Gulbenkian Institute for Science (IGC)

Monica Bettencourt-Dias – Principal Investigator & Former Director, Gulbenkian Institute for Science (IGC)

The funding landscape for science in Portugal is facing challenges that stem from a decrease in overall investment and shifting priorities. Despite the evident role of blue-sky research, exemplified by important contributions to critical advancements like RNA vaccines, there has not been a corresponding increase in funding
See more

In Case You Missed It

InFigures

Apart from a maturing regulatory environment and the expansion of healthcare coverage across the region, a number of other factors are contributing to the evolution of the MEA pharma market. Results from the second wave of a PhRMA-commisioned IQVIA market access study covering Saudi Arabia (KSA), UAE, Kuwait, Lebanon, Jordan, Egypt, Algeria, Morocco, Tunisia and…

Belgium, with a total of EUR 5.5 billion in R&D spending in 2021, is the country with the fourth largest research expenditure in the EU and the first per inhabitant.  As a recent study from Deloitte sponsored by the Belgian pharmaceutical industry association, pharma.be, shows, Belgium is also a leader in clinical trials, maintaining its…

The top 10 Indian pharma companies ranked by market capitalization as of June 2023, compiled by Global Data. Way out in front is Sun Pharma, followed by Dr Reddy’s and Cipla. Made with Visme Infographic Maker

The subject of intense industry criticism from the likes of lobby groups, Big Pharma, and biotech alike, the Inflation Reduction Act (IRA) subjects certain drugs to price negotiations directly with industry sponsors in the US for the first time. Ten initial drugs – which accounted for over USD 45 billion in Medicare Part D spending…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here